Off-Pump versus On-Pump Coronary Artery Bypass Grafting Outcomes Stratified by Preoperative Renal Function

Lakhmir S. Chawla,*† Yue Zhao,‡ Fredrick C. Lough,§ Elizabeth Schroeder,* Michael G. Seneff,* and J. Matthew Brennan‡|

*Department of Anesthesiology and Critical Care Medicine, George Washington University Medical Center, Washington, DC; †Division of Renal Diseases and Hypertension, Department of Medicine, George Washington University Medical Center, Washington, DC; ‡Outcomes Research and Assessment Group, Duke Clinical Research Institute, Durham, North Carolina; §Division of Cardiothoracic Surgery, George Washington University Medical Center, Washington, DC; and ‖Division of Cardiovascular Medicine, Duke University Medical Center, Durham, North Carolina

ABSTRACT
Clinical trials of off-pump coronary artery bypass grafting (CABG) have largely excluded patients with CKD. Here, we sought to determine whether pump status affects outcomes in patients with CKD. Using a nonrandomized cohort of 742,909 non-emergent, isolated CABG cases, which included 158,561 off-pump cases, in the Society of Thoracic Surgery Database from 2004 through 2009, we evaluated the association between pump status (off-pump versus on-pump) and in-hospital death or incident renal replacement therapy (RRT) across strata of preoperative renal function. We used propensity methods to adjust patient- and center-level analyses for imbalances in baseline patient risk. Patients who received on-pump and off-pump CABG had similar mean age and distribution of preoperative estimated GFR (eGFR). In a propensity-weighted analysis, off-pump CABG was associated with a reduction in the composite in-hospital death or RRT, with patients having lower preoperative renal function exhibiting greater benefit, on average. The risk difference (on-pump minus off-pump) ranged from 0.05 (95% confidence interval, −0.06 to 0.16) per 100 patients for eGFR $\geq$90 ml/min per 1.73 m² to 3.66 (95% confidence interval, 2.14–5.18) per 100 patients for eGFR 15–29 ml/min per 1.73 m². Both component endpoints suggested the same trend. In summary, these data suggest that patients with CKD experience less death or incident RRT when treated with off-pump compared with on-pump CABG. The reduction in incident RRT, not death, drove this effect on the composite among patients with low eGFR. Prospective trials comparing these procedures in patients with impaired preoperative renal function are warranted.


AKI complicates 2.3% of isolated CABG cases, with an incidence as high as 14%–15% among patients with preoperative CKD.¹ Although a progression to stage 3 AKI (e.g., such as renal replacement therapy [RRT]) is rare, it is associated with a 50%–70% in-hospital mortality and up to 50% of patients need chronic dialysis.²,³
Because prolonged cardiopulmonary bypass (CPB) time has been associated with postoperative AKI, some have advocated the use of off-pump coronary artery bypass (OPCAB) techniques for high-risk patients. Although randomized trials of OPCAB have not demonstrated benefits in a general population,⁴,⁵ patients with CKD have

Received February 3, 2012. Accepted March 25, 2012.
Published online ahead of print. Publication date available at www.jasn.org.
Correspondence: Dr. Lakhmir S. Chawla, Department of Anesthesiology and Critical Care Medicine, George Washington University Medical Center, 900 23rd Street NW, RIF, Room G-105, Washington, DC 20037. Email: lchawla@mfa.gwu.edu
Copyright © 2012 by the American Society of Nephrology
composed <10% of those studied, including <8% of those in the recent Veterans Affairs Randomized On/Off Bypass (ROOBY) trial.4

In this analysis, we examined a nationally representative patient cohort who underwent elective, isolated CABG at 1000 centers in the Society of Thoracic Surgeons Adult Cardiac Surgery Database (STS ACSD) to test the following hypotheses: (1) off-pump procedures are associated with a lower incidence of cardiac surgery–associated AKI compared with on-pump CABG, and (2) the degree of renal protection associated with off-pump CABG is directly related to the extent of preoperative renal dysfunction.

RESULTS

Patient Characteristics

Of the 742,909 patients who underwent non-emergent, isolated CABG at 1000 STS ACSD centers, 158,561 (21.4%) included an intended off-pump approach (Figure 1). An unplanned cross-over from off-pump to on-pump procedures was observed in 2.9% of patients in the off-pump cohort, and the following reasons were cited for unintended cross-over: inadequate exposure or visualization (19.3%), bleeding (3.1%), inadequate size and/or diffuse distal vessel disease (7.1%), hemodynamic instability (60.2%), poor conduit quality and/or trauma (3.0%), and other reasons (7.3%). Conversion patients experienced a higher incidence of both in-hospital death (5.4%) and RRT (2.9%) than the remaining OPCAB cohort (Table 1).

Compared with on-pump coronary artery bypass (ONCAB) patients, OPCAB patients were slightly older and more often

Table 1. Unadjusted associations between treatment received and outcome and between center preference and outcome

<table>
<thead>
<tr>
<th>Event</th>
<th>Treatment Received</th>
<th>Center Preference Analysis</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>On Pump</td>
<td>Off Pump</td>
</tr>
<tr>
<td></td>
<td>Patients and Events (n)</td>
<td>%</td>
</tr>
<tr>
<td>Overall cohort</td>
<td>584,348</td>
<td>158,561</td>
</tr>
<tr>
<td>death or RRT</td>
<td>11,665</td>
<td>2.0</td>
</tr>
<tr>
<td>death</td>
<td>7849</td>
<td>1.3</td>
</tr>
<tr>
<td>RRT</td>
<td>5724</td>
<td>1.0</td>
</tr>
<tr>
<td>eGFR ≥90</td>
<td>141,859</td>
<td>36,729</td>
</tr>
<tr>
<td>death or RRT</td>
<td>1236</td>
<td>0.9</td>
</tr>
<tr>
<td>death</td>
<td>1006</td>
<td>0.7</td>
</tr>
<tr>
<td>RRT</td>
<td>408</td>
<td>0.3</td>
</tr>
<tr>
<td>eGFR 60–89</td>
<td>301,603</td>
<td>80,968</td>
</tr>
<tr>
<td>death or RRT</td>
<td>4025</td>
<td>1.3</td>
</tr>
<tr>
<td>death</td>
<td>3186</td>
<td>1.1</td>
</tr>
<tr>
<td>RRT</td>
<td>1488</td>
<td>0.5</td>
</tr>
<tr>
<td>eGFR 30–59</td>
<td>133,129</td>
<td>37,959</td>
</tr>
<tr>
<td>death or RRT</td>
<td>5160</td>
<td>3.9</td>
</tr>
<tr>
<td>death</td>
<td>3253</td>
<td>2.4</td>
</tr>
<tr>
<td>RRT</td>
<td>2794</td>
<td>2.1</td>
</tr>
<tr>
<td>eGFR 15–29</td>
<td>7757</td>
<td>2905</td>
</tr>
<tr>
<td>death or RRT</td>
<td>1244</td>
<td>16.0</td>
</tr>
<tr>
<td>death</td>
<td>404</td>
<td>5.2</td>
</tr>
<tr>
<td>RRT</td>
<td>1034</td>
<td>13.3</td>
</tr>
</tbody>
</table>

^aNumber of patients with the outcome per 100 patients treated on pump minus number of patients with the outcome per 100 patients treated off pump.

^bNumber of patients with the outcome per 100 patients treated at centers with a preference for on-pump CABG (on-pump centers) minus the number of patients with the outcome per 100 patients treated at centers with a preference for off-pump CABG (off-pump centers).
female, with a lower burden of both comorbidities and coronary artery disease (CAD) (Table 2), including a higher incidence of one-vessel (10.6% versus 2.4%; \( P<0.001 \)) and two-vessel disease (25.0% versus 18.0%; \( P<0.001 \)). CKD was present in a significant proportion of the overall cohort, with an estimated GFR (eGFR) of 30–59 in 22.8% and an eGFR of 15–29 in 1.3%; however, baseline renal function was similar across the two treatment groups. After propensity weighting, demographics and baseline comorbidities were well balanced across treatment groups in the overall cohort (Table 2), as well as among each of the four eGFR strata.

In-Hospital Outcomes

Death or Incident RRT

In the overall cohort, the incidence of in-hospital death or need for new RRT was 2.0%, with a slightly lower incidence observed in the off-pump versus on-pump cohorts (1.8% versus 2.0%; risk difference in on-pump minus off-pump, 0.20; 0.12–0.27) (Table 1). Patients with the poorest preoperative renal function had the highest incidence of in-hospital death or RRT (Table 1). The attributable benefit for in-hospital death or incident RRT associated with OPCAB (versus ONCAB) was progressively greater across strata of worsening baseline renal function. Using both propensity weighting and a center-level approach, this result was durable and remained statistically significant (Table 3 and Figures 2 and 3).

In-Hospital Mortality

In the overall cohort, the observed incidence of in-hospital mortality was slightly lower among patients treated with off-pump versus on-pump CABG (1.2% versus 1.3%; risk difference, 0.10; 0.04–0.16) (Table 1). The unadjusted incidence of mortality in patients with a reduced eGFR (15–29 and 30–59) was lowest among the OPCAB (versus ONCAB) cohort (3.5% versus 5.2% and 2.2% versus 2.4%, respectively); however, the incidence was similar among patients with a preserved eGFR (60–89, 1.0% versus 1.1%; ≥90, 0.7% versus 0.7%). Although the associated survival advantage of OPCAB among low eGFR patients was maintained in the propensity analysis, no difference in survival was observed when the center-level analysis was performed (Table 3).

Incident RRT

In the overall cohort, the incidence of new RRT was 1.0%, with a slightly lower incidence observed among OPCAB (versus ONCAB) patients (0.9% versus 1.0%; risk difference, 0.13; 0.08–0.18) (Table 1). Patients with the poorest preoperative renal function experienced the highest incidence of postoperative RRT (Table 1). The

---

Table 2. Characteristics of patients stratified by intended use of cardiopulmonary bypass pump

<table>
<thead>
<tr>
<th>Characteristic</th>
<th>On-Pump (n=584,348)</th>
<th>Baseline (n=158,561)</th>
<th>Standardized Difference (%)a</th>
<th>Propensity Weighted</th>
<th>Standardized Difference (%)a</th>
<th>P Value</th>
</tr>
</thead>
<tbody>
<tr>
<td>Age (yr), median (IQR)</td>
<td>65 (58, 73)</td>
<td>66 (58, 74)</td>
<td>6.5</td>
<td>0.1</td>
<td>0.83</td>
<td></td>
</tr>
<tr>
<td>Female (%)</td>
<td>26.2</td>
<td>29.4</td>
<td>7.1</td>
<td>0.01</td>
<td>0.99</td>
<td></td>
</tr>
<tr>
<td>BSA, median (IQR)</td>
<td>2.0 (1.8, 2.2)</td>
<td>2.0 (1.8, 2.1)</td>
<td>8.8</td>
<td>0.02</td>
<td>0.95</td>
<td></td>
</tr>
<tr>
<td>Hypertension</td>
<td>82.7</td>
<td>82.6</td>
<td>0.2</td>
<td>0.2</td>
<td>0.44</td>
<td></td>
</tr>
<tr>
<td>Diabetes</td>
<td>38.6</td>
<td>36.2</td>
<td>4.9</td>
<td>0.2</td>
<td>0.45</td>
<td></td>
</tr>
<tr>
<td>Chronic lung disease</td>
<td>21.7</td>
<td>21.9</td>
<td>0.5</td>
<td>0.5</td>
<td>0.09</td>
<td></td>
</tr>
<tr>
<td>eGFR</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>≥90</td>
<td>24.3</td>
<td>23.2</td>
<td>2.6</td>
<td>0.03</td>
<td>0.93</td>
<td></td>
</tr>
<tr>
<td>60–89</td>
<td>51.6</td>
<td>51.1</td>
<td>1.1</td>
<td>0.1</td>
<td>0.85</td>
<td></td>
</tr>
<tr>
<td>30–59</td>
<td>22.8</td>
<td>23.9</td>
<td>2.7</td>
<td>0.02</td>
<td>0.95</td>
<td></td>
</tr>
<tr>
<td>15–29</td>
<td>1.3</td>
<td>1.8</td>
<td>4.0</td>
<td>0.1</td>
<td>0.78</td>
<td></td>
</tr>
<tr>
<td>Prior cardiovascular surgery</td>
<td>4.9</td>
<td>3.9</td>
<td>3.9</td>
<td>0.4</td>
<td>0.23</td>
<td></td>
</tr>
<tr>
<td>Prior MI</td>
<td>43.9</td>
<td>41.6</td>
<td>0.6</td>
<td>0.1</td>
<td>0.80</td>
<td></td>
</tr>
<tr>
<td>CHF</td>
<td>12.8</td>
<td>13.1</td>
<td>0.7</td>
<td>0.1</td>
<td>0.62</td>
<td></td>
</tr>
<tr>
<td>Ejection fraction, median (IQR)</td>
<td>55 (45, 60)</td>
<td>55 (45, 60)</td>
<td>6.8</td>
<td>0.7</td>
<td>0.02</td>
<td></td>
</tr>
<tr>
<td>Left main &gt;50%</td>
<td>30.8</td>
<td>28.3</td>
<td>5.4</td>
<td>0.1</td>
<td>0.81</td>
<td></td>
</tr>
<tr>
<td>CAD; no. of vessels</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>1</td>
<td>2.4</td>
<td>10.6</td>
<td>33.6</td>
<td>0.01</td>
<td>0.97</td>
<td></td>
</tr>
<tr>
<td>2</td>
<td>18.0</td>
<td>25.0</td>
<td>17.1</td>
<td>0.2</td>
<td>0.38</td>
<td></td>
</tr>
<tr>
<td>3</td>
<td>79.4</td>
<td>64.0</td>
<td>34.6</td>
<td>0.2</td>
<td>0.42</td>
<td></td>
</tr>
<tr>
<td>Procedure status</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>elective</td>
<td>47.9</td>
<td>51.9</td>
<td>7.2</td>
<td>0.4</td>
<td>0.24</td>
<td></td>
</tr>
<tr>
<td>urgent</td>
<td>52.1</td>
<td>48.6</td>
<td>7.2</td>
<td>0.4</td>
<td>0.24</td>
<td></td>
</tr>
</tbody>
</table>

IQR, interquartile range; BSA, body surface area; MI, myocardial infarction; CHF, congestive heart failure; CAD, coronary artery disease.

*Calculated as difference in group means divided by an estimate of the pooled SD; rounded to the first significant digit after the decimal point.
Table 3. Conventional and instrumental variable estimates of the risk difference (on pump minus off pump) associated with on-pump versus off-pump CABG

<table>
<thead>
<tr>
<th>Event</th>
<th>Conventional Unadjusted</th>
<th>Conventional Propensity Weighteda</th>
<th>Unadjusted Center Preference Analysis</th>
<th>Adjusted Center Preference Analysis</th>
</tr>
</thead>
<tbody>
<tr>
<td>Overall cohort</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>death or RRT</td>
<td>0.20 (0.12, 0.27)b</td>
<td>0.28 (0.21, 0.36)b</td>
<td>0.18 (0.02, 0.34)c</td>
<td>0.03 (-0.21, 0.26)</td>
</tr>
<tr>
<td>death</td>
<td>0.10 (0.04, 0.16)d</td>
<td>0.15 (0.09, 0.21)b</td>
<td>0.06 (-0.08, 0.20)</td>
<td>-0.07 (-0.27, 0.13)</td>
</tr>
<tr>
<td>RRT</td>
<td>0.13 (0.08, 0.18)b</td>
<td>0.18 (0.13, 0.24)b</td>
<td>0.18 (0.07, 0.29)d</td>
<td>0.13 (-0.03, 0.29)</td>
</tr>
<tr>
<td>eGFR ≥90</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>death or RRT</td>
<td>0.07 (-0.03, 0.18)</td>
<td>0.05 (-0.06, 0.16)</td>
<td>0.26 (0.06, 0.46)d</td>
<td>0.10 (-0.21, 0.41)</td>
</tr>
<tr>
<td>death</td>
<td>0.05 (-0.05, 0.14)</td>
<td>0.04 (-0.06, 0.13)</td>
<td>0.20 (0.02, 0.38)c</td>
<td>0.08 (-0.20, 0.36)</td>
</tr>
<tr>
<td>RRT</td>
<td>0.07 (0.02, 0.13)c</td>
<td>0.05 (-0.01, 0.11)</td>
<td>0.09 (-0.02, 0.20)</td>
<td>0.08 (-0.06, 0.23)</td>
</tr>
<tr>
<td>eGFR 60-89</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>death or RRT</td>
<td>0.16 (0.08, 0.25)b</td>
<td>0.14 (0.05, 0.23)d</td>
<td>0.01 (-0.18, 0.20)</td>
<td>-0.26 (-0.57, 0.06)</td>
</tr>
<tr>
<td>death</td>
<td>0.10 (0.03, 0.18)c</td>
<td>0.09 (0.02, 0.17)c</td>
<td>-0.06 (-0.23, 0.12)</td>
<td>-0.28 (-0.57, 0.00)</td>
</tr>
<tr>
<td>RRT</td>
<td>0.07 (0.02, 0.12)d</td>
<td>0.05 (-0.00, 0.11)</td>
<td>0.09 (-0.01, 0.19)</td>
<td>0.01 (-0.17, 0.19)</td>
</tr>
<tr>
<td>eGFR 30-59</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>death or RRT</td>
<td>0.58 (0.38, 0.79)b</td>
<td>0.66 (0.45, 0.87)b</td>
<td>0.43 (-0.04, 0.90)</td>
<td>0.28 (-0.38, 0.94)</td>
</tr>
<tr>
<td>death</td>
<td>0.20 (0.03, 0.37)c</td>
<td>0.30 (0.12, 0.47)b</td>
<td>0.21 (-0.16, 0.59)</td>
<td>0.16 (-0.34, 0.65)</td>
</tr>
<tr>
<td>RRT</td>
<td>0.46 (0.31, 0.61)b</td>
<td>0.47 (0.31, 0.62)b</td>
<td>0.36 (0.03, 0.70)c</td>
<td>0.22 (-0.32, 0.75)</td>
</tr>
<tr>
<td>eGFR 15-29</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>death or RRT</td>
<td>3.65 (2.20, 5.10)b</td>
<td>3.66 (2.14, 5.18)b</td>
<td>4.73 (1.64, 7.82)d</td>
<td>4.60 (0.53, 8.68)c</td>
</tr>
<tr>
<td>death</td>
<td>1.73 (0.90, 2.56)b</td>
<td>1.92 (1.06, 2.78)b</td>
<td>1.14 (-0.70, 2.98)</td>
<td>-0.36 (-3.60, 2.88)</td>
</tr>
<tr>
<td>RRT</td>
<td>2.76 (1.41, 4.11)b</td>
<td>2.79 (1.37, 4.20)b</td>
<td>4.02 (1.17, 6.87)c</td>
<td>4.49 (1.07, 7.91)d</td>
</tr>
</tbody>
</table>

aInverse probability weighted estimates after balancing treatment groups using propensity score.

bP value <0.001.
cP value <0.05.
dP value <0.01.

The associated benefit of OPCAB (versus ONCAB) for incident RRT was greatest among patients with impaired preoperative renal function (Table 1). This pattern was statistically significant and maintained in both the propensity and center-level analyses (Table 3).

Among the patients who developed an incident need for RRT, those with the poorest preoperative renal function experienced better survival compared with those with more intact preoperative renal function (Table 4).

**DISCUSSION**

Randomized trials comparing on-pump versus off-pump CABG have not demonstrated a consistent benefit of off-pump techniques; however, these trials have included limited samples of patients with reduced renal function, a group in whom off-pump procedures may confer an acute benefit. In this large, contemporary cohort of isolated CABG patients, we have shown that OPCAB is associated with reduced in-hospital mortality or incident RRT among patients with CKD, a result driven by a reduction in the need for postoperative RRT. In this cohort, the benefit of OPCAB was inversely related to the baseline renal function (Table 3), and although patients with CKD experienced a stepwise benefit with a dose-response effect, those patients with normal renal function experienced no associated benefit (Figures 2 and 3). These data are not inconsistent with prior randomized trials and suggest a need for further evaluation in patients at high risk for postoperative AKI.

The link between CPB and AKI is plausible, especially among patients with limited preoperative renal reserve. Low mean arterial pressures (<60 mmHg) commonly maintained during CPB may be particularly deleterious in CKD patients with known impairments in renal autoregulation. In the setting of reduced perfusion, kidneys with impaired autoregulation are more vulnerable to ischemia, particularly in the low oxygen renal medulla. In addition, nonpulsatile renal perfusion, microemboli, and systemic inflammation associated with extracorporeal therapies may contribute to postoperative AKI. Despite this mechanistic association, prospective controlled trials of off-pump CAGB have included few patients with CKD (Table 5).

Prior studies examining the association between pump status and postoperative renal function have been inconclusive. However, these studies have been generally underpowered to examine the association in patients with CKD. The ROOBY trial, which remains the largest randomized comparison of off-pump versus on-pump CAGB, did not show a benefit of OPCAB for postoperative renal function; however, <8% of the patients enrolled in this study had pre-existing CKD. In the one dedicated assessment of pump status among
patients with preoperative CKD, Sajja et al. observed an association between OPCAB and improved renal outcomes. Congruent with both of these studies, we have demonstrated that OPCAB is only associated with renal protection in patients with impaired preoperative renal function. This finding may explain some of the heterogeneity of effects observed across prior studies.

Renalism is a term coined by Chertow et al. in 2004 and refers to the notion that high-risk patients with kidney disease tend “receive more conservative therapy for cardiovascular diseases, even though the relative benefits of therapy tend to be greater” (p 2462). Although CKD has a stronger association with cardiovascular events than any of the classic Framingham risk factors (i.e., family history, hypercholesterolemia, smoking, hypertension, and diabetes mellitus), patients with CKD have been systematically excluded from large cardiovascular clinical trials. In some cases, this trend has been a function of concern for increased toxicity of cardiovascular medications in patients with impaired metabolite clearance; in others, it has been a function of perceived therapeutic futility. Certainly, caution is always appropriate when considering the inclusion of patients with high-risk features in clinical trials; however, our findings reaf-frm that a systematic exclusion of these patients is ill advised when a plausible mechanistic link suggests additive therapeutic benefit in one or more of the high-risk subgroups.

Among patients requiring incident RRT, a higher associated incidence of in-hospital mortality was observed among those with more intact preoperative renal function compared with those with a lower baseline eGFR. These results are provocative and are consistent with a prior analysis demonstrating worse outcomes among critically ill patients who develop incident AKI requiring RRT compared with similarly matched critically ill patients with baseline ESRD who required RRT. The mechanism underlying this observation is unclear; further speculation is beyond the scope of this report. Future studies should be conducted to further elaborate on this observation and test potential mechanistic pathways.
This analysis has many strengths, including robust CKD subgroups and an intention-to-treat design, but it also has several limitations. Most importantly, this study is retrospective in design. Without randomized treatment allocation, imbalances in unmeasured patient characteristics may have biased our results. In fact, the center preference analysis suggests that a portion of the OPCAB mortality benefit observed in the propensity-weighted analysis may have been the result of residual bias. However, confirmation of the benefit of OPCAB on the postoperative incidence of RRT with both propensity score and center-level analyses adds validity to these results. Second, although the observed rate of off-pump to on-pump cross-over in this cohort (2.9%) was within the bounds of previously reported studies, it is substantially lower than the 12% cross-over rate reported by the ROOBY investigators. The bias that may have resulted from inclusion of these additional cross-over cases in the on-pump cohort was directly addressed by our center preference analysis. In addition, extra precautions were taken to ensure the results were not biased by center effects associated with the treatment strategy preference. Finally, OPCAB has a significant learning curve, and the nuances of individual center and surgical team effects are not easily captured in this type of analysis. However, on average, OPCAB was associated with a reduction in the need for postoperative RRT in this cohort. To test our hypothesis that OPCAB compared with ONCAB improves renal outcomes and survival in CKD patients, we believe that an appropriately powered prospective study should be conducted. Based on our analysis, the number of patients needed for such a study would range from 1300 to 7000 patients depending on the incidence of RRT/death rate, effect size, and power (Supplemental Appendix 1).

In conclusion, OPCAB is associated with a lower incidence of postoperative RRT compared with ONCAB in patients with poor preoperative renal function. Future efforts should focus on an assessment of risks and benefits in this high-risk subgroup.

**Figure 3.** Instrumental variable estimates associated with on-pump versus off-pump CABG. (A) Inhospital mortality or need for RRT. (B) Inhospital mortality. (C) Need for RRT. *P<0.05. **P<0.01, ***P<0.001.
CONCISE METHODS

Data Sources and Patient Population
Since 1989, the STS ACSD has collected perioperative data on cardiac operations at hospitals across North America as a part of a continuous quality improvement effort. The ACSD ensures high-quality data through an independent auditing process, which has verified 96% correlation between ACSD data and that obtained through a conventional patient-level propensity analysis and a center-level analysis in which the exposure variable was center preference for on-pump versus off-pump procedures.

For this analysis, we examined patients undergoing non-emergent, isolated CABG from January 1, 2004, through December 31, 2009. We excluded patients with cardiacogenic shock and those with a preoperative eGFR <15 ml/min per 1.73 m² or those who were receiving dialysis preoperatively. Patients were also excluded when missing data for CPB utilization, preoperative serum creatinine, postoperative dialysis, postoperative renal failure, or in-hospital mortality.

Unadjusted and adjusted comparisons of OPCAB versus ONCAB were estimated in the overall cohort and within each of the following four eGFR subgroups: (1) eGFR 15–29 ml/min per 1.73 m², (2) eGFR 30–59 ml/min per 1.73 m², (3) eGFR 60–89 ml/min per 1.73 m², and (4) eGFR ≥90 ml/min per 1.73 m². The Duke University School of Medicine Institutional Review Board granted a waiver of informed consent and authorization for this study.

Data Definitions
The STS ACSD collects information on in-patient mortality and morbidity, including the need for dialysis and postoperative renal failure. Detailed definitions of risk factors and complications are provided on the STS web site (www.sts.org). Preoperative eGFR is based on the last serum creatinine closest to the date and time of the CABG procedure, as collected within the STS ACSD. OPCAB was defined as an intent to operate on pump, including patients undergoing CABG with no CPB, or unplanned use of CPB as collected in the data collection form. Likewise, the ONCAB group was defined as patients with planned CPB utilization. eGFR was calculated using the Modified Diet in Renal Disease equation, and was based on available preoperative data.

Study End Points
Because of the nontrivial competing risk of in-hospital death in this population, the primary outcome for this study was a composite of in-hospital death and incident in-hospital RRT. Secondary outcomes included the two component endpoints of in-hospital mortality and RRT.

Statistical Analyses
We estimated the effect of CPB on in-hospital death and incident RRT using a conventional patient-level propensity analysis and a center-level analysis in which the exposure variable was center preference for on-pump versus off-pump procedures.

Propensity Score Analysis (Patient-Level)
The on-pump and off-pump groups were compared using risk difference (in percentages), that is, the estimated probability difference (on-pump group minus the off-pump group) between two groups. Propensity scores were estimated by fitting a nonparsimonious logistic model within the overall cohort (c statistic 0.63) and each of the four eGFR strata (eGFR 15–29: c statistic, 0.65; eGFR 30–59: c statistic, 0.63; eGFR 60–89: c statistic, 0.63; eGFR ≥90: c statistic, 0.64). The five-number summaries (minimum, 20th percentile, median, 80th percentile, maximum) describing propensity score distributions for on-pump and off-pump treatment groups were as follows: eGFR 15–29 (0.06, 0.18, 0.24, 0.33, and 0.88 versus 0.09, 0.21, 0.29, 0.41, and 0.81), eGFR 30–59 (0.05, 0.15, 0.20, 0.26, and 0.80 versus 0.08, 0.17, 0.23, 0.32, and 0.78), eGFR 60–89 (0.07, 0.15, 0.20, 0.24, and 0.76 versus 0.08, 0.16, 0.21, 0.30, and 0.80), and eGFR ≥90 (0.07, 0.14, 0.18, 0.23, and 0.74 versus 0.001).
0.07, 0.16, 0.21, 0.30, and 0.82) (Supplemental Appendix 2). The high
degree of overlap across treatment groups suggests that the use of
propensity score methods was appropriate in this cohort. In this
case, the propensity score represented the estimated probability of
receiving OPCAB (versus ONCAB) as a function of the patient’s
baseline demographics and comorbidities as well as preoperative
cardiac medications (70 observed covariates; Supplemental Appendix
3). Adjusted risk differences were estimated using linear models,
including a single covariate for treatment and weighting each ob-
servation by the inverse of the estimated propensity score.28 When
estimating 95% confidence intervals, robust sandwich variance es-
timates were used to account for the patients’ dependence with
sites. The balance of baseline characteristics achieved across the
two treatment groups after propensity weighting was assessed
through visual inspection of propensity distributions and through
an evaluation of the standardized difference (defined as difference
in group means divided by an estimate of the pooled SD). There
was a high degree of overlap of the distribution of propensity scores
for each of the treatment groups in the overall cohort and in each
of the eGFR strata. Observed differences in covariates across the
treatment groups were small, and in all cases were <5% of the
estimated SD, indicating a good balance of baseline risk factors.27
To further limit bias from treatment selection, patients were ex-
cluded if their propensity score was outside the area of treatment
group overlap, as previously described.28

Center Preference Analysis (Center-Level)
Although the STS ACSD collects data on conversion from an in-
tended off-pump to on-pump approach, conversion was indicated
in only 2.9% of off-pump cases (versus 12.4% in the recently pub-
lished ROOBY trial4), raising the concern that a substantial pro-
portion of off-pump to on-pump conversions were recorded as
on-pump procedures in the database. A strong association between
unplanned conversion and poor operative outcomes was previously
demonstrated,29 which would bias our analysis results against the
on-pump technique. A center preference analysis was performed to
address both the potential bias introduced by cross-over proce-
dures and the likely unmeasured confounding associated with
the treatment selection. In this analysis, we used center preference
for on-pump versus off-pump procedures as the exposure of in-
terest. To the extent that outcomes across these centers varied only
as the effect of preference for on-pump versus off-pump proce-
dures, this analysis would produce an unbiased estimate of the
effect of pump status on outcomes. An institutional preference
for off-pump CABG was defined as the use of off-pump techniques
in >90% of CABG cases, to allow for a 10% expected rate of off-
pump to on-pump conversion.4 Likewise, an institutional pre-
ference for on-pump CABG was defined as the use of on-pump
techniques in >95% of CABG cases, to allow for a 5% incidence of
factors such as a heavily calcified aorta that may compel an un-
planned off-pump approach. Regardless of the actual CPB usage,
all of the cases from the 51 centers preferring an off-pump strategy
were compared with cases from the 347 centers preferring an on-
pump strategy. The comparison of observed patient characteris-
tics at on-pump versus off-pump centers revealed minor differences,
including a slightly lower proportion of three-vessel disease at off-
pump centers (Supplemental Appendix 4). A comparison of out-
comes of a common and relevant on-pump procedure (aortic valve
replacement plus CABG) across on-pump versus off-pump centers
revealed no significant difference in outcomes across these two
types of centers (Supplemental Appendix 5), suggesting that the
centers preferring on-pump versus off-pump techniques are not
systematically different in overall surgical skill and quality of care
delivered. Despite these results suggesting general similarities in
patient characteristics and center-level outcomes, we used propen-
sity score methods to risk adjust this analysis for both patient-level
covariates (n=70) and the estimated center-specific random ef-
effects, in which the center-specific random effects were estimated
using a hierarchical model for in-hospital motility within the aortic
valve replacement plus CABG procedures. The propensity score
was the probability of a patient being in an on-pump versus off-
pump center. Both unadjusted and risk-adjusted estimates were
calculated for each of the primary and secondary endpoints.

Descriptive statistics are based on nonmissing values and pre-
vented as median and interquartile range (25th to 75th percentile) for
continuous variables, or frequency and percentage for categorical
variables. The Wilcoxon rank sum test compared the distribution of
continuous variables, whereas the Mantel–Haenszel test was used for
categorical variable comparisons. Missing data were rare (<0.5% for
all variables). Missing values of body surface area and body mass index
were imputed to sex-specific median values. Missing values of ejection
fraction were imputed to sex-specific median values for patients with
known congestive heart failure, were otherwise imputed to 50%. Miss-
ing values of the remaining risk factors were defaulted to their most
common value. SAS statistical software (version 9.1; SAS Institute,
Cary, NC) was used for all calculations.

ACKNOWLEDGMENTS

The authors thank Richard Amdur for reviewing this manuscript.

DISCLOSURES

None.

REFERENCES

Normand SL, DeLong ER, Shewan CM, Dokholyan RS, Peterson ED,
Edwards FH, Anderson RP; Society of Thoracic Surgeons Quality
cardiac surgery risk models: Part 1—coronary artery bypass grafting
2. Lassnigg A, Schmidlin D, Mouhieddine M, Bachmann LM, Druml W,
Bauer P, Hiesmayr M: Minimal changes of serum creatinine predict
prognosis in patients after cardiothoracic surgery: A prospective cohort
3. Rosner MH, Okusa MD: Acute kidney injury associated with cardiac


